Ultimovacs to ride wave of positive momentum in 2022

Ultimovacs’ Q4 report has been released and it reflects the company’s robust progress with its universal cancer vaccine candidate UV1 during 2021. This, paired with important regulatory decisions by the FDA, has given Ultimovacs positive momentum going into 2022. The company’s CEO Carlos de Sousa spoke to BioStock about the company´s achievements and how he plans to keep up the strong momentum into 2022.

Read the full article here